A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab ...

A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant anti-psoriatic therapies or have recently transitioned from systemic therapies 1% effort 6 subjects

Awarded By

  • Genentech

Contributors

Amount

  • $46,716.00

Start/End

  • January 2004 - September 2005